{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T15:45:06Z","timestamp":1742399106595},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,25]]},"DOI":"10.7759\/cureus.47628","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T09:28:50Z","timestamp":1698226130000},"source":"Crossref","is-referenced-by-count":1,"title":["Concomitant Use of Steroids and Immunotherapy in a Patient With Paraneoplastic Dermatomyositis and Gastroesophageal Adenocarcinoma"],"prefix":"10.7759","author":[{"given":"Fernando","family":"Poli De Frias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan Keith","family":"Petit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Polit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Poppiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Sesin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-015-0120-1","article-title":"Cancer risk in dermatomyositis: a meta-analysis of cohort studies","volume":"16","author":"Olazagasti JM","year":"2015","unstructured":"Olazagasti JM, Baez PJ, Wetter DA, Ernste FC. Cancer risk in dermatomyositis: a meta-analysis of cohort studies. Am J Clin Dermatol. 2015, 16:89-98. 10.1007\/s40257-015-0120-1","journal-title":"Am J Clin Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip M","year":"2017","unstructured":"Philip M, Fairchild L, Sun L, et al.. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017, 545:452-6. 10.1038\/nature22367","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920937612","article-title":"Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials","volume":"12","author":"Zhao B","year":"2020","unstructured":"Zhao B, Zhao H, Zhao J. Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials. Ther Adv Med Oncol. 2020, 12:1758835920937612. 10.1177\/1758835920937612","journal-title":"Ther Adv Med Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos FX","year":"2018","unstructured":"Danlos FX, Voisin AL, Dyevre V, et al.. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018, 91:21-9. 10.1016\/j.ejca.2017.12.008","journal-title":"Eur J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg IE","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, et al.. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017, 76:1955-64. 10.1136\/annrheumdis-2017-211468","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2018.1531188","article-title":"Clinical significance of myositis-specific autoantibodies","volume":"41","author":"Nakashima R","year":"2018","unstructured":"Nakashima R. Clinical significance of myositis-specific autoantibodies. Immunol Med. 2018, 41:103-12. 10.1080\/25785826.2018.1531188","journal-title":"Immunol Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura Y","year":"2012","unstructured":"Ichimura Y, Matsushita T, Hamaguchi Y, et al.. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012, 71:710-3. 10.1136\/annrheumdis-2011-200697","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22978","article-title":"The role of myositis-specific autoantibodies in the dermatomyositis spectrum","volume":"14","author":"Marasandra Ramesh H","year":"2022","unstructured":"Marasandra Ramesh H, Gude SS, Venugopal S, Peddi NC, Gude SS, Vuppalapati S. The role of myositis-specific autoantibodies in the dermatomyositis spectrum. Cureus. 2022, 14:e22978. 10.7759\/cureus.22978","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian YY","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al.. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021, 398:27-40. 10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim ST","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, et al.. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018, 24:1449-58. 10.1038\/s41591-018-0101-z","journal-title":"Nat Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02321-z","article-title":"Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer","volume":"68","author":"Kehl KL","year":"2019","unstructured":"Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol Immunother. 2019, 68:917-26. 10.1007\/s00262-019-02321-z","journal-title":"Cancer Immunol Immunother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals M","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, et al.. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020, 6:38. 10.1038\/s41572-020-0160-6","journal-title":"Nat Rev Dis Primers"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat M","year":"2018","unstructured":"Touat M, Maisonobe T, Knauss S, et al.. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. 2018, 91:e985-94. 10.1212\/WNL.0000000000006124","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09118-3","article-title":"Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study","volume":"22","author":"Sano A","year":"2022","unstructured":"Sano A, Sohda M, Nakazawa N, et al.. Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study. BMC Cancer. 2022, 22:22. 10.1186\/s12885-021-09118-3","journal-title":"BMC Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.08.005","article-title":"Endogenous glucocorticoid signaling regulates CD8(+) T cell differentiation and development of dysfunction in the tumor microenvironment","volume":"53","author":"Acharya N","year":"2020","unstructured":"Acharya N, Madi A, Zhang H, et al.. Endogenous glucocorticoid signaling regulates CD8(+) T cell differentiation and development of dysfunction in the tumor microenvironment. Immunity. 2020, 53:658-671.e6. 10.1016\/j.immuni.2020.08.005","journal-title":"Immunity"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour KC","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N, et al.. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018, 36:2872-8. 10.1200\/JCO.2018.79.0006","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma","volume":"27","author":"Iorgulescu JB","year":"2021","unstructured":"Iorgulescu JB, Gokhale PC, Speranza MC, et al.. Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma. Clin Cancer Res. 2021, 27:276-87. 10.1158\/1078-0432.CCR-20-2291","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.10.009","article-title":"Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: a systematic review","volume":"120","author":"Garant A","year":"2017","unstructured":"Garant A, Guilbault C, Ekmekjian T, Greenwald Z, Murgoi P, Vuong T. Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: a systematic review. Crit Rev Oncol Hematol. 2017, 120:86-92. 10.1016\/j.critrevonc.2017.10.009","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti B","year":"2019","unstructured":"Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol. 2019, 37:1927-34. 10.1200\/JCO.19.00189","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/191049-concomitant-use-of-steroids-and-immunotherapy-in-a-patient-with-paraneoplastic-dermatomyositis-and-gastroesophageal-adenocarcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:07:55Z","timestamp":1707509275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/191049-concomitant-use-of-steroids-and-immunotherapy-in-a-patient-with-paraneoplastic-dermatomyositis-and-gastroesophageal-adenocarcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.47628","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,25]]}}}